Evidence map›Paper›PMID 38902203›Full record

ArticleThe Journal of international medical research2024

Mismatch repair protein deficiency in triple-negative breast carcinomas.

Bayan Maraqa, Maxim Al-Ashhab, Hamza Zughaier, Fareed Barakat, Majd Khader, Hussein Al Maaitah, Ruba Alabweh, Maher Sughayer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bayan MaraqaDepartment of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.ORCID 0000-0001-9455-188X
Maxim Al-AshhabDepartment of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.
Hamza ZughaierDepartment of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.
Fareed BarakatDepartment of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.
Majd KhaderDepartment of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.
Hussein Al MaaitahDepartment of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.
Ruba AlabwehDepartment of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.
Maher SughayerDepartment of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.ORCID 0000-0002-9185-9616

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer, particularly triple-negative breast cancer (TNBC), poses a significant global health burden. Chemotherapy was the mainstay treatment for TNBC patients until immunotherapy was introduced. Studies indicate a noteworthy prevalence (0.2% to 18.6%) of mismatch repair protein (MMRP) deficiency in TNBC, with recent research highlighting the potential of immunotherapy for MMRP-deficient metastatic breast cancer. This study aims to identify MMRP deficiency in TNBC patients using immunohistochemistry.

methodsA retrospective cohort study design was used and included TNBC patients treated between 2015 and 2021 at King Hussein Cancer Center. Immunohistochemistry was conducted to assess MMRP expression.

resultsAmong 152 patients, 14 (9.2%) exhibited deficient MMR (dMMR). Loss of PMS2 expression was observed in 13 patients, 5 of whom showed loss of MLH1 expression. Loss of MSH6 and MSH2 expression was observed in one patient. The median follow-up duration was 44 (3-102) months. Despite the higher survival rate (80.8%, 5 years) of dMMR patients than of proficient MMR patients (62.3%), overall survival did not significantly differ between the two groups.

conclusionApproximately 9% of TNBC patients exhibit dMMR. dMMR could be used to predict outcomes and identify patients with TNBC who may benefit from immunotherapy.

Indexed as

DNA-Binding ProteinsDNA Mismatch RepairMismatch Repair Endonuclease PMS2Triple Negative Breast NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansImmunohistochemistryMiddle AgedMutL Protein Homolog 1MutS Homolog 2 ProteinPrognosisRetrospective StudiesBiomarkers, TumorDNA-Binding ProteinsG-T mismatch-binding proteinMismatch Repair Endonuclease PMS2MLH1 protein, humanMSH2 protein, humanMutL Protein Homolog 1MutS Homolog 2 ProteinPMS2 protein, humanbreast cancerimmunohistochemistryimmunotherapymicrosatellite instabilitymismatch repair deficiencyTriple negative

Identifiers

PMID38902203
PMCPMC11193345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.